Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DRYS: the queen of all short squeezes is coming. This will be a never-seen-before event. Could go to $100/share and higher.
Very good news indeed, certainly when we know that the p-value is between 0.01 and 0.05 considering it was an efficacy comparison with Tropol XL and not with placebo (most phase 2b trials compare vs placebo)
That is right. It's my post. I just could not copy it ??
510(k) approval will come right now.Read the post from AlexanderJohannes: https://www.stocktwits.com/symbol/AMDA
From Stocktwits DKtrader:AMEDICA in Brasil:http://www.sintexmedical.com.br
AMDA ready to go +$1/share:recent Australian FDA approval en huge increase in ownership. Easy x3 in share price. Good trade and long term hold. http://www.nasdaq.com/symbol/amda/institutional-holdings
Institutional intrest increased substantially! http://www.nasdaq.com/symbol/amda/institutional-holdings
Here is the summary of todays' filing;
The aggregate market value of our Common Shares held by non-affiliates pursuant to General Instruction I.B.5 of Form F-3 is $47,047,253, which was calculated based on 14,102,204 of our Common Shares outstanding and held by non-affiliates as of the date of this Prospectus and a price of $3.35 per share, the closing price of our Common Shares on NASDAQ on February 17, 2017. We have sold 2,073,507 Common Shares pursuant to General Instruction I.B.5 of Form F-3 during the twelve calendar month period that ends on and includes the date of this Prospectus and the aggregate value of the Common Shares sold was $7,108,188.
Page 13-15 http://s1.q4cdn.com/221711767/files/doc_presentations/2017/Cytori-Corp-FEB-2017-Final_021417.pdf. It must be painful paying millions of dollars for a takeover (Azaya) and you see that one of their pipeline products is already outdated
CYTX just did a horrible dilution. I will tell you why: the liposomal Doxorubicin pipeline they received from a recent takeover will never be used because word is out that Zoptrex results are going to be great. Just an educated guess of course. But the timeline supports it.
Look to the history of different biotech companies: all dilute before bad news.
If they would expect the news was good, they would have gotten the same amount of money without diluting this many shares.
If yhe expect the news is bad, they dilute before news, because other wise the share price implodes and it gets much more difficult to raise capital.
It is going to be bad news from EMA. IMO.
Loool,they just received a $1m milestone payment. Probably all the revenue they are going to make in 2017. EMA CRL coming. You just don't dilute before such an important milestone if you think it is going to be positive.
Short squeeze possible today if MM's work together
Exactly.They're starting it now expecting positive Macrilen news, so that they don not need all 3 million shares to get $9million
ATM programm starts:max issuance of 3,000,000 shares for $9million.Very good news, means that the company expects good news
Don't buy till after EMA CRL, the next round of dilution (it'll be toxic, back against the wall) and the R/S 1:10. Crossover design for TIVO-1 is terrible
If data are good,share price will rise to $30-40/share to start with.
If both data are bad, we're screwed.
Obviously I think both data will be good, because otherwise I wouldn't be investing in this company.
Probably somewhere between 4-10million shares will be issued ATM for $50million. They will probably do that on the same trading day that positive news on Mac and Zoptrex is announced. This is a very, very, very strategical move. I love it!
Announcement of prolonging their ATM programm which would have ended this month. Possible $50million capital raise through At The Market trading.
That is good news IMO, much better than by dilution through warrants or a 40% discount. Management looks pretty confident by prefering this way to raise capital.
"According to ASCO in 2015, best option for EC 2nd line treatment was… enrolling in the ZoptEC trial, no joke!"
http://ascopubs.org/doi/full/10.1200/JCO.2015.61.7225
Great Post from maggie_on_rails on stocktwits
My takeaway from the CC: Sufficient money to continue operation until at least the start of commercialization of Zoptrex and Macrilen (if approved). Great CC, Dodd sounded very confident. IMO management has a lot of faith that Macrilen and Zoptrex (overall survival of Zoptrex + specific methods of the oncologists will be higher than Dox + specific method of the oncologists). Only 13.5 million shares outstanding.
If Macrilen gets a yes from the FDA and if Zoptrex results are positive, share price will be $40/share to start with
Great earning report!Tons of cash left, no debt and only 13,5 million shares outstanding! If Macrilen and Zoptrex are positive,first stop will be $40/share
http://ir.aezsinc.com/press-release/aeternazentaris/aeterna-zentaris-reports-fourth-quarter-and-full-year-2016-financial
Since Doxorubicin is also used in the treatment for prostate and ovarian cancer, the P3 results for endometrial cancer will determine the entire future of AEZS. If Zoptrex shows significant efficacy and safety vs Doxorubicin now,it will garantee success for prostate and ovarian cancer as well. In other words success should be valued in a MC above 1billion dollar. 1 billion dollar/20 million shares (included 7million shares extra as dilution)= $50/share
another disillusion:a 1:10 reverse split.
Thanks. That makes my day
President Trump: Replace The Dollar With Gold As The Global Currency To Make America Great Again.
https://www.forbes.com/sites/ralphbenko/2017/02/25/president-trump-replace-the-dollar-with-gold-as-the-global-currency-to-make-america-great-again/#5f9578f94d54
I agree.
IMO gold is going to retest 2016 highs and break it. Going to 1450/1500.
Banks still having problems,Greece still in financial trouble, the UK going for a cold Brexit, possible Nexit/Frexit, Trumps' protectionism, ... Gold prices will explode, NUGT will followx3
Since it has a SPA protocol,it will be 180days (instead of 360 days) after the company files the NDA. The NDA will soon be filed after the study results. (New Drug Application).
I really do think that AEZS will be worth ++$20/share if the P3 results are positive. It will happen between the release of the results and the final FDA decision. This is the Adam Feuerstein biotech oncology rule.
The rule is that the company has to reach a market cap of at least $300m somewhere between the phase 3 results and the final FDA decision.
AEZS:potential 6-/10-bagger this year:If phase3 for Zoptrex shows succesfull results in April, share price of AEZS will be ++$20/share afterwarts (before FDA decision). This because of the Adam Feuerstein biotech oncology rule: The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps< $300M. https://www.google.be/amp/s/www.thestreet.com/amp/story/12696926/1/the-feuerstein-ratain-rule-update-still-perfect-predicting-small-cap-cancer-drug-failure.html?client=safari
APRIL is the month:If P3 for Zoptrex shows succesfull results in April, share price of AEZS will be ++$20/share afterwarts (before FDA decision). This because of the Adam Feuerstein biotech oncology rule: The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps< $300M. https://www.google.be/amp/s/www.thestreet.com/amp/story/12696926/1/the-feuerstein-ratain-rule-update-still-perfect-predicting-small-cap-cancer-drug-failure.html?client=safari
50 DMA (.623) last week, 100 DMA (.673) crossed yesterday and today the 200 DMA (.811) has been crossed in a bullish manner. Volume increasing day by day, insider buying reported, excellent 180LOI news for the registration of TIVO in 1st line renal cel carcinoma in the EU (EUSA seems comfortable) and a great presentation from Needle.
Today the 100DMA(0.678)has been succesfully broken in a bullish manner. And what a statement the market has made: it has been broken on a volume which is more than twice the 3 month average volume!
AVEO breached its' 50DMA in a bullish manner (0,62). It breached it after Thursday news. It means the market expects the 180LOI of the EMA can be adequately answered and that EMA approval for the treatment of renal cancer carcinoma (RCC) in 1st line in Europa is imminent.
I agree. But more like 10dollars/share
Results of their clinical trials